Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 87

1.

Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial.

Ejlertsen B, Tuxen MK, Jakobsen EH, Jensen MB, Knoop AS, Højris I, Ewertz M, Balslev E, Danø H, Vestlev PM, Kenholm J, Nielsen DL, Bechmann T, Andersson M, Cold S, Nielsen HM, Maae E, Carlsen D, Mouridsen HT.

J Clin Oncol. 2017 Aug 10;35(23):2639-2646. doi: 10.1200/JCO.2017.72.3494. Epub 2017 Jun 29.

PMID:
28661759
2.

Filaggrin loss-of-function mutations, atopic dermatitis and risk of actinic keratosis: results from two cross-sectional studies.

Andersen YMF, Egeberg A, Balslev E, Jørgensen CLT, Szecsi PB, Stender S, Kaae J, Linneberg A, Gislason G, Skov L, Elias PM, Thyssen JP.

J Eur Acad Dermatol Venereol. 2017 Jun;31(6):1038-1043. doi: 10.1111/jdv.14172. Epub 2017 Mar 6.

PMID:
28213896
3.

Expression Patterns of Biomarkers in Primary Tumors and Corresponding Metastases in Breast Cancer.

Kümler I, Balslev E, Knop AS, Brünner N, Klausen TW, Jespersen SS, Nielsen SL, Nielsen DL.

Appl Immunohistochem Mol Morphol. 2016 Oct 7. [Epub ahead of print]

PMID:
27753656
4.

High-Risk Premenopausal Luminal A Breast Cancer Patients Derive no Benefit from Adjuvant Cyclophosphamide-based Chemotherapy: Results from the DBCG77B Clinical Trial.

Nielsen TO, Jensen MB, Burugu S, Gao D, Jørgensen CL, Balslev E, Ejlertsen B.

Clin Cancer Res. 2017 Feb 15;23(4):946-953. doi: 10.1158/1078-0432.CCR-16-1278. Epub 2016 Sep 6.

PMID:
27601592
5.

Time trends in axilla management among early breast cancer patients: Persisting major variation in clinical practice across European centers.

Gondos A, Jansen L, Heil J, Schneeweiss A, Voogd AC, Frisell J, Fredriksson I, Johansson U, Tvedskov TF, Jensen MB, Balslev E, Hartmann-Johnsen OJ, Sant M, Baili P, Agresti R, van de Velde T, Broeks A, Nogaret JM, Bourgeois P, Moreau M, Mátrai Z, Sávolt Á, Nagy P, Kásler M, Schrotz-King P, Ulrich C, Brenner H.

Acta Oncol. 2016 Jun;55(6):712-9. doi: 10.3109/0284186X.2015.1136751. Epub 2016 Feb 15.

PMID:
26878397
6.

Risk of non-sentinel node metastases in patients with symptomatic cancers compared to screen-detected breast cancers.

Tvedskov TF, Jensen MB, Balslev E, Garne JP, Vejborg I, Christiansen P, Ejlertsen B, Kroman N.

Acta Oncol. 2016;55(4):455-9. doi: 10.3109/0284186X.2015.1094186. Epub 2015 Oct 9.

PMID:
26452696
7.

Prognostic significance of axillary dissection in breast cancer patients with micrometastases or isolated tumor cells in sentinel nodes: a nationwide study.

Tvedskov TF, Jensen MB, Ejlertsen B, Christiansen P, Balslev E, Kroman N.

Breast Cancer Res Treat. 2015 Oct;153(3):599-606. doi: 10.1007/s10549-015-3560-7. Epub 2015 Sep 4.

PMID:
26341752
8.
9.

Topoisomerase-1 gene copy aberrations are frequent in patients with breast cancer.

Kümler I, Balslev E, Poulsen TS, Nielsen SL, Nygård SB, Rømer MU, Christensen IJ, Høgdall E, Moreira J, Nielsen DL, Brünner N, Stenvang J.

Int J Cancer. 2015 Oct 15;137(8):2000-6. doi: 10.1002/ijc.29556. Epub 2015 Apr 27.

10.

Reduced risk of axillary lymphatic spread in triple-negative breast cancer.

Holm-Rasmussen EV, Jensen MB, Balslev E, Kroman N, Tvedskov TF.

Breast Cancer Res Treat. 2015 Jan;149(1):229-36. doi: 10.1007/s10549-014-3225-y. Epub 2014 Dec 9.

PMID:
25488719
11.

miR-21 Expression in Cancer Cells may Not Predict Resistance to Adjuvant Trastuzumab in Primary Breast Cancer.

Nielsen BS, Balslev E, Poulsen TS, Nielsen D, Møller T, Mortensen CE, Holmstrøm K, Høgdall E.

Front Oncol. 2014 Aug 15;4:207. doi: 10.3389/fonc.2014.00207. eCollection 2014.

12.

Differential expression of miR-139, miR-486 and miR-21 in breast cancer patients sub-classified according to lymph node status.

Rask L, Balslev E, Søkilde R, Høgdall E, Flyger H, Eriksen J, Litman T.

Cell Oncol (Dordr). 2014 Jun;37(3):215-27. doi: 10.1007/s13402-014-0176-6. Epub 2014 Jul 16.

PMID:
25027758
13.

Prognosis of synchronous bilateral breast cancer: a review and meta-analysis of observational studies.

Holm M, Tjønneland A, Balslev E, Kroman N.

Breast Cancer Res Treat. 2014 Aug;146(3):461-75. doi: 10.1007/s10549-014-3045-0. Epub 2014 Jul 10. Review.

PMID:
25007962
14.

Phase II study of neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide ± trastuzumab followed by docetaxel in locally advanced breast cancer.

Tuxen MK, Cold S, Tange UB, Balslev E, Nielsen DL.

Acta Oncol. 2014 Oct;53(10):1440-5. doi: 10.3109/0284186X.2014.921727. Epub 2014 Jul 3. No abstract available.

PMID:
24991893
15.

TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group.

Jørgensen CL, Bjerre C, Ejlertsen B, Bjerre KD, Balslev E, Bartels A, Brünner N, Nielsen DL.

BMC Cancer. 2014 May 22;14:360. doi: 10.1186/1471-2407-14-360.

16.

Individuals with complete filaggrin deficiency may have an increased risk of squamous cell carcinoma.

Kaae J, Szecsi PB, Meldgaard M, Espersen ML, Stender S, Johansen JD, Bandier J, Thyssen JP, Menné T, Nielsen SL, Høgdall E, Balslev E, Skov L.

Br J Dermatol. 2014 Jun;170(6):1380-1. doi: 10.1111/bjd.12911. No abstract available.

PMID:
24641578
17.

Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization for Low and High Throughput HER2 Genetic Testing.

Poulsen TS, Espersen ML, Kofoed V, Dabetic T, Høgdall E, Balslev E.

Int J Breast Cancer. 2013;2013:368731. doi: 10.1155/2013/368731. Epub 2013 Dec 5.

18.

Reliability of histological malignancy grade, ER and HER2 status on core needle biopsy vs surgical specimen in breast cancer.

Munch-Petersen HD, Rasmussen BB, Balslev E.

APMIS. 2014 Sep;122(9):750-4. doi: 10.1111/apm.12213. Epub 2013 Dec 21.

PMID:
24372587
19.

PAM50 breast cancer intrinsic subtypes and effect of gemcitabine in advanced breast cancer patients.

Jørgensen CL, Nielsen TO, Bjerre KD, Liu S, Wallden B, Balslev E, Nielsen DL, Ejlertsen B.

Acta Oncol. 2014 Jun;53(6):776-87. doi: 10.3109/0284186X.2013.865076. Epub 2013 Dec 20.

PMID:
24359601
20.

Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine.

Jørgensen CL, Ejlertsen B, Bjerre KD, Balslev E, Nielsen DL, Nielsen KV.

BMC Cancer. 2013 Nov 12;13:541. doi: 10.1186/1471-2407-13-541.

Supplemental Content

Loading ...
Support Center